OVERVIEW: The Alan B. Slifka Foundation funds a wide array of biomedical research studies concerning sarcoma, melanoma, Autism and Asperger’s Syndrome.
IP TAKE: This funder tends to devote a good deal of its research dollars to large institutions.
PROFILE: Cofounder of Halcyon Asset Management, Alan B. Slifka, established the Alan B Slifka Foundation in 1965 to help create “[a] world safe for difference.” Initially, the foundation focused its grantmaking on Judaism and Israel but has since expanded to “[t]he pursuit of inclusion, diversity, peace and healing.” Slifka’s current funding priorities include fostering an equitable shared society, diversity and tolerance in Israel, Jewish life in Israel and the United States and research related to sarcoma, melanoma, Asperger Syndrome and Autism.
The foundation’s Sarcoma Research Grants Initiative invests in a diverse set of topics including but not limited to translational studies, vaccine studies, the molecular biology of sarcomas, drug resistance, novel sarcoma therapies, early detection and diagnosis. The peer review process for this grant takes approximately two to four months. Slifka does not specify which types of research it funds in related to Autism and Asperger Syndrome. On a smaller scale, the foundation also funds other disease-related organizations beyond its funding scopes, such as cystic fibrosis and leukemia.
The majority of grants range in amount from $10,000 to $100,000; however, research grants for sarcoma cannot exceed $50,000. Past grantees include the Mary Crowley Cancer Research Center and the International Society for Autism Research.
The Slifka Foundation accepts one to two-page letters of inquiry for grant requests concerning sarcoma, melanoma, Asperger Syndrome and Autism. It does not accept unsolicited requests for funding for its other grantmaking programs.
Search for staff contact info and bios in PeopleFinder (paid subscribers only).